Defective healing of chronic wounds is a serious clinical problem; for example, decubitus and leg ulcers afflict roughly 5 million people in the US alone. Normal wound repair depends on molecules like fibronectin to promote cell adhesion and migration (1). This large adhesive glycoprotein provides a crucial substrate for many forms of cell migration, such as in embryonic migratory pathways and in the provisional matrix of healing wounds. Besides acting as a substrate, fibronectin also has certain proteolytic fragments that can promote chemotactic migration (e.g., see ref. 2), and fibronectin or its fragments can also activate integrin signaling (reviewed in refs. 3, 4). Because fibronectin augments cell migration, ideas for stimulating wound repair have included soaking wound dressings in fibronectin, providing fibronectin in eye drops, and developing synthetic polymeric substrates that contain biologically active fragments of the fibronectin sequence. A dream for many in the field has been to apply fibronectin peptides, which can be synthesized and potentially combined in various ways to generate specificity, to wound repair and tissue engineering. Conversely, inhibitory peptides could also be used to block unwanted processes such as tumor cell invasion and metastasis (11). Conventional thought in this field has focused on the use of fibronectin or its mimetics as adhesive and migration substrates in wounds (Figure 2, left). A very different approach is proposed by Livant and coworkers in this issue of the JCI (5).

These authors focused on the PHSRN (Pro-His-Ser-Arg-Asn) sequence of fibronectin, because their initial antibody inhibition studies suggested a role for this sequence in activating cell invasion. PHSRN had been characterized previously as a “synergy” sequence that cooperated with the RGD sequence in mediating effective inte-

![Diagram](image-url)
grin-mediated cell adhesion and migration (12–14). In contrast to conventional thinking, Livant et al. (5) report that this fibronectin peptide has remarkably potent activity in triggering invasion of fibroblasts or keratinocytes across a heterologous (invertebrate-derived) basement membrane. Moreover, low doses of the peptide activate wound repair in vivo in a murine model. Chemically blocking the charged NH₂- and COOH-termini of the peptide (which helps peptides better mimic a sequence within a polypeptide chain) resulted in the highest activity. These findings contrast markedly with those in earlier studies, which demonstrated much lower activity for PHSRN peptides in inhibiting cell adhesion competitively or in mediating direct adhesion (14). These earlier studies were consistent with the dogma that PHSRN represents a minimal version of the overall synergy region, whereas the present study reports peptide activities more than tenfold higher than even the original protein (5), suggesting that cells can bind PHSRN with much higher affinity than the usual affinity of integrins for fibronectin. Livant et al. further propose that proteolysis of fibronectin releases PHSRN or a related peptide (5), which could have potent local chemotactic and cell invasive activity for promoting normal wound repair. This notion remains speculative, but it is not without precedent: Other peptides, derived from fibronectin, laminin, or other extracellular matrix proteins, have been shown to induce expression of collagenase or to promote angiogenesis and metastasis (8, 15, 16), and some of these peptides are cryptic in the intact protein, becoming active only after proteolysis or when presented as synthetic peptides. Although PHSRN may function similarly, it should be noted that the effective concentrations of these other bioactive peptides are considerably higher than the nanomolar range used by Livant et al.

The most impressive findings of Livant et al. (5) involve acceleration of in vivo wound repair. Because wound repair is often impaired in diabetics, they tested the effects of PHSRN peptides on wound healing in a genetically obese diabetic mouse model. They report that a single treatment with 2 μg of the short Ac-PHSRN-NH₂ peptide dramatically stimulates repair, accelerating impaired closure of 4-mm punch biopsy wounds from 20–42 days to only 8 days. This peptide, but not a randomized version, enhanced keratinocyte and fibroblast migration into the wounds and improved vascularization. Treatment with this peptide also slightly accelerated wound closure in the control heterozygous mice. Whether similar enhancement of wound repair will be seen in other wound healing systems remains to be determined.

Interestingly, this group has also recently shown that a similar peptide, modified by an arginine–cysteine substitution to generate an inhibitor, reversed tumor metastases in rats (17). These striking stimulatory and inhibitory results with PHSRN derivatives in vivo contrast with the general experience that small peptides are not ideal candidates for therapeutics because they diffuse rapidly and undergo prompt renal clearance, as found for another fibronectin peptide (18). However, it is possible that a dry wound might retain peptides; in this regard, tracer studies on the half-life of the PHSRN peptides in wounds will be quite informative. Other questions for the future include establishing which integrin is involved in vivo, the nature of any signaling pathways activated by this reagent, the mechanism by which cell migration is stimulated, and the significance of heightened migration or invasion for the reported effects in accelerating wound repair.

Because these imaginative studies by Livant and coworkers (5, 17) challenge orthodoxy and report such impressive acceleration of wound healing (and reversal of metastasis) in animal models, they will arouse considerable interest and, possibly, controversy. Nevertheless, the authors seem to have made a good case for their novel approaches, and it is now up to the field to test them. It is important to establish promptly whether these potentially exciting results represent a major breakthrough or a temporary detour in the quest for creative therapies to alleviate clinical problems in wound repair.

fibronectin for human monocytes resides in the 120-kDa fibroblastic cell-binding fragment. *J. Biol. Chem.* **263:**12115–12123.


